Shots:
- The EC has approved Afqlir(2mg vial kit & pre-filled syringe for intravitreal injection), biosimilar of Bayer’s Eylea (aflibercept), with the launch anticipated in Q4’25
- Afqlir’s biosimilar development program included analytical, preclinical & clinical data from the Mylight trial, establishing its equivalence in terms of efficacy & safety to the reference medicine
- Aflibercept is a recombinant fusion protein that inhibits abnormal vessel growth by binding with VEGF-A & placental growth factor (PlGF), enhancing visual acuity & inhibiting disease progression
Ref: Sandoz | Image: Sandoz | Press Release
Related News:- Samsung Bioepis and Biogen Report the EC’s Approval of Opuviz (Biosimilar, Eylea)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
